Eurofins-Cerep SA (FR:ALECR) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Eurofins Cerep SA reported a decrease in 2023 revenue by 7.47% to 44,069 million euros, down from 47,628 million euros in 2022, with an operating profit of 6.46 million euros, also noting a decline from the previous year’s 11.48 million euros. Despite the market slowdown, the company is expanding through new platforms and strategic initiatives like ‘DiscoveryOne’ and partnerships with the University of Poitiers. Eurofins Cerep remains a leader in in-vitro pharmacology and is enhancing its integrated drug discovery services, offering comprehensive solutions to the pharmaceutical industry.
For further insights into FR:ALECR stock, check out TipRanks’ Stock Analysis page.